Lupin Digital Health's Lyfe Platform receives Class C medical device license from CDSCO
India, April 25 -- Lupin Digital Health, India's first evidence-based cardiology Digital Therapeutics (DTx) platform, has announced that its Lyfe platform has received approval as a Class C Medical Device from the Central Drugs Standard Control Organization (CDSCO). This milestone marks a groundbreaking advancement in post-discharge integrated care, highlighting the potential of evidence-based digital therapeutics solutions to transform patient care.
Having undergone a rigorous application, review, and on-site audit process, this Class C Medical Device license reaffirms the platform's effectiveness and emphasizes its commitment to quality, safety, and rigour.
Lyfe is now India's first clinically proven remote cardiac rehabilitation prog...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.